A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of intravenous Mircera,
administered with pre-filled syringes, for the treatment of anemia in patients with chronic
kidney disease who are on dialysis, and who have previously received treatment with epoetin
alfa or beta or darbepoetin alfa. Patients will receive monthly intravenous injections of
Mircera, with the starting dose derived from the dose of epoetin alfa or beta or darbepoetin
they were receiving in the week preceding study start. The anticipated time on study
treatment is 3-12 months, and the target sample size is 500+ individuals.